PMID- 36288846
OWN - NLM
STAT- MEDLINE
DCOM- 20221031
LR  - 20221031
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 11
DP  - 2022 Nov
TI  - Intravascular Administration of Acridine Orange and Zoledronate in a Bone 
      Metastasis Model of Breast Cancer.
PG  - 5357-5363
LID - 10.21873/anticanres.16041 [doi]
AB  - BACKGROUND/AIM: This study evaluated the effect of haematogenous administration 
      of acridine orange (AO) alone and in combination with zoledronate (ZOL) on bone 
      metastases. MATERIALS AND METHODS: E0771 cells (1.0x10(5) cells/10 mul) were 
      injected directly into the right femur of female mice. The mice were divided into 
      five groups according to treatment (drugs and irradiation) and were reared and 
      sacrificed after 6 weeks. Micro-computed tomography (muCT) was performed to 
      calculate the destruction rate of the femur bone. We measured tumour weight and 
      volume at sacrifice and performed terminal deoxynucleotidyl transferase dUTP 
      Nick-End Labelling staining of tumours. RESULTS: At 4 weeks, the bone destruction 
      rate was lower in the AO+ZOL group than in the radiation group. At 6 weeks, the 
      AO+ZOL group had a lower bone destruction rate than the control and radiation 
      groups; the ZOL group had a lower rate than the radiation group. The AO and 
      AO+ZOL groups had suppressed tumour weight and volume compared to the control and 
      radiation groups. The number of extraosseous apoptotic cells was higher in the 
      AO+ZOL group than in all other groups except the AO group. CONCLUSION: In a model 
      of local bone metastasis of breast cancer, haematogenous administration of AO 
      reduced tumour size and more so when combined with ZOL.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Shoji, Ryo
AU  - Shoji R
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan yebyayayeby@gmail.com.
FAU - Tsuchie, Hiroyuki
AU  - Tsuchie H
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Nagasawa, Hiroyuki
AU  - Nagasawa H
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Hongo, Michio
AU  - Hongo M
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Kasukawa, Yuji
AU  - Kasukawa Y
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Nozaka, Koji
AU  - Nozaka K
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Kudo, Daisuke
AU  - Kudo D
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Saito, Hikaru
AU  - Saito H
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Abe, Kazunobu
AU  - Abe K
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Igarashi, Shun
AU  - Igarashi S
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Harata, Shuntaro
AU  - Harata S
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Kasama, Fumihito
AU  - Kasama F
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Miyakoshi, Naohisa
AU  - Miyakoshi N
AD  - Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - F30N4O6XVV (Acridine Orange)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - EC 2.7.7.31 (DNA Nucleotidylexotransferase)
RN  - 0 (Imidazoles)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Animals
MH  - Female
MH  - Mice
MH  - Acridine Orange/therapeutic use
MH  - *Bone Density Conservation Agents/therapeutic use
MH  - *Bone Neoplasms/drug therapy/secondary
MH  - Diphosphonates
MH  - DNA Nucleotidylexotransferase
MH  - Imidazoles/therapeutic use
MH  - *Osteolysis/drug therapy
MH  - X-Ray Microtomography
MH  - Zoledronic Acid/therapeutic use
MH  - *Breast Neoplasms/drug therapy
OTO - NOTNLM
OT  - Acridine orange
OT  - breast cancer
OT  - metastasis
OT  - zoledronate
EDAT- 2022/10/27 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/10/26 20:53
PHST- 2022/06/15 00:00 [received]
PHST- 2022/09/10 00:00 [revised]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/26 20:53 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
AID - 42/11/5357 [pii]
AID - 10.21873/anticanres.16041 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Nov;42(11):5357-5363. doi: 10.21873/anticanres.16041.